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1. Introduction
  Mycobacterium tuberculosis is one of the most threatening 
of human infectious diseases, and 2 million people die 
from tuberculosis every year[1]. No new drug has been 
licensed for tuberculosis for half a century and no new 
vaccine has been licensed for more than three-quarters 
of a century. The cell wall of Mycobacterium tuberculosis 
composed of peptidoglycan, arabinogalactan and mycolic 
acids complex is essential for proliferation and growth[2]. 
Some of the first-line tuberculosis drugs target cell wall 
synthesis in Mycobacterium tuberculosis, but their specific 
targets and mechanisms of inhibition are not well defined. 
The rhamnose-GlcNAc disaccharide linker connects the 
galactan of arabinogalactan to the peptidoglycan. The 
donor dTDP-L-rhamnose is synthesized by four enzymes 
(RmlA, RmlB, RmlC, and RmlD) beginning with glucose-
1-phosphate (Glu-1-p) and dTTP[3,4]. The function of 
L-rhamnosyltransferase encoded by Rv3265c gene is 
transfering dTDP-L-rhamnose residue to GlcNAc to form 
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disaccharide linker, which is essential for Mycobacterium 
tuberculosis viability[5,6]. The pathway of biosynthetic 
L-rhamnose and rhamnose-GlcNAc which is highly 
conserved in Gram-positive and Gram-negative bacteria 
does not present in humans, so enzymes of the pathways 
are very attractive targets for antimycobacterial drugs and 
possible vaccines[7]. In order to study the function of this 
enzyme, we expressed Rv3265c gene in Escherichia coli (E. 
coli) strain and predicted the characteristics and structure of 
L-rhamnosyltransferase using bioinformatics methods.
2. Materials and methods 
2.1. Bacterial strains, plasmids, cultivation and enzymes
  Genomic DNA from Mycobacterium tuberculosis H37Rv 
was kindly provided by Lab Director ZY Zhu of Affiliated 
Xinhua Hospital of Hainan Medical University. E. coli 
DH5毩 (TaKaRa Biotechnology) was used for cloning, 
transformation and propagation. E.coli BL21 (DE3) (Merck) 
and plasmid pET30-a (Merck) were used for protein 
expression. All E. coli strains were grown in LB broth 
or on LB plate with 1.5% (wt/vol) agar 37 曟 or 30 曟,
respectively. When needed, kanamycin was used at final 
concentration of 50 毺g/mL for E. coli. Restriction enzymes 
(BamHI, SacI), PrimeSTARTM HS DNA Polymerase, T4 ligase 
and Taq DNA Polymerase were purchased from TaKaRa 
Biotechnology.  
2.2. Amplification of Rv3265c gene
  The nucleotide sequence of Rv3265c gene was obtained 
from Mycobacterium tuberculosis H37Rv genome (http://
genolist.pasteur.fr/TubercuList/). Genomic DNA from 
Mycobacterium tuberculosis H37Rv was used as template 
in the PCR. A pair of primers, TB Rv3265c-F (5 ′-
CGCGGATCCATGGTAGCGGTGACCTACTCGC-3′) and TB 
Rv3265c-R (5′-TCCGAGCTCTCAGTGCCGCCCTTCTACCAGC
T-3′) contained BamHI and SacI endonuclease restriction 
sites (underlined) were used for amplification. PCR was 
performed by using PrimeSTARTM HS DNA polymerase as 
follow conditions: 94 曟 for 5min, 30 cycles (94 曟 30 s; 65 曟 
40 s; 72 曟 1 min), and then 72 曟 for 10 min. 
2.2. Construction of expression plasmid
  The PCR product was purified by using an agarose gel DNA 
fragment recovery kit (Tiangen, Beijing, China), according 
to the manufacturer protocol. And then, purified PCR 
products digested with BamHI and SacI was cloned into the 
pET30-a vector resulting in plasmid pET30-Rv3265c, and 
chemically transformed into the E. coli DH5毩 cells using 
standard procedures. Recombinant plasmid pET30-Rv3265c 
was identified by PCR and restriction endonuclease, and 
then sequenced to confirm that no base changes had been 
introduced during amplification of the DNA.
2.3. Expression of Rv3265c gene in E. coli
  The recombinant plasmid pET30-Rv3265c was transformed 
into competent E. coli BL21 (DE3) cells and screened on 
LB agar plates containing kanamycin. Individual colonies 
of the transformants were grown in LB broth at 37 曟. The 
overnight grown cultures were subcultured in fresh medium 
at 30 曟 to the density of OD600≈0.6. Cells were induced with 
IPTG (TaKaRa Biotechnology) at final concentration of 0.1 
mM for various induction periods of 1, 2 and 3 h at 30 曟. 
After induction, cells were harvested by centrifugation, 
and then whole-cell proteins of the induced and control 
cells were analyzed on 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). To visualize 
proteins, gels were stained 30 min with 0.05% Coomassie 
blue, and then destained with 10% acetic acid and 25% 
isopropanol. In order to examine the extent of aggregation of 
the produced, induced cells were disrupted by sonication for 
5 min on ice and soluble as well as insoluble fractions were 
analyzed using SDS-PAGE as described previously. 
2.4. Protein purification and Western blotting analysis
  The soluble fractions were applied to column volume 
HIS-Select HF affinity gel (Sigma), and then the column 
was washed with wash buffer. The protein was eluted with 
15 mL elute buffer with 1毺M leupeptin, 1毺M pepstatin 
A, and 1mM PMSF as the manufacturer’s protocol. The 
purified protein was run on 12% SDS-PAGE and transferred 
to nitrocellulose membrane. After blocking with 5% 
nonfat dry milk, the membrane was probed with 1:3000 
dilution of mouse anti-polyhistidine monoclonal HIS-1 
antibody (Sigma) followed by 1:5000 dilution of horseradish 
peroxidase(HRP) -conjugated goat anti-mouse IgG antibody 
(Sigma).The membrane was checked by utilizing the 3,3’-
diaminobenzidine liquid substrate system.
2.5. Bioinformatics analysis of Rv3265c gene and protein
  All of nucleotide and amino acid sequences in this 
study were from the National Center for Biotechnology 
Information (http://www.ncbi.nlm.nih.gov). The multiple 
protein sequence homological alignment was carried out 
using the ClustalW program (http://www.ebi.ac.uk/clustalw). 
Signal peptides, cleavage sites and subcellular location 
were predicted by the SignalP program, TargetP program 
and TMHMM program, respectively (http://www.cbs.dtu.
dk/). Conserved domains and motif were predicted by Motif 
scan program (http://myhits.isb-sib.ch/cgi-bin/motif_
scan), InterProScan program (http://www.ebi.ac.uk/Tools/
InterProScan/) and Pfam program (http://pfam.sanger.ac.uk/) 
together. Antigenic epitopes were predicted by Predicting 
Antigenic Peptides program (http://bio.dfci.harvard.edu/
Tools/antigenic.html) and Abie Pro 3.0 program (http://www.
changbioscience.com/abie/abie.html). Secondary structure 
and topology was predicted by PredictProtein program 
(http://www. Predictprotein.org/), ANTHEPROT 2000 software 
(http://antheprot-pbil.ibcp.fr/), COILS program (http://www.
ch.embnet.org/software/COILS_form.html). Tertiary structure 
was established using SWISS-MODEL (http://swissmodel.
expasy.org/) and RasTop 2.2 software (http://www.
geneinfinity.org/rastop/) based on homology modeling. Basic 
physical and chemical properties analysis and phylogenetic 
analysis was analyzed using Vector NTI Advance 10 
software (Invitrogen, USA) and Geneious Pro 3.8.5 software 
(Biomatters, USA).
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3. Results 
3.1. Molecular cloning of Rv3265c gene
  Rv3265c gene was amplified by PCR (Figure 1A). DMSO has 
been added to PCR reaction buffer to enhance denaturation 
of GC rich template DNA and to aid polymerase extension 
through the secondary structures in our testing. The resulting 
fragment contained about 915 bp and had an open reading 
frame encoding 301 amino acids. The Rv3265c gene was 
then cloned into pET30-a. The recombinant plasmid pET30-
Rv3265c was identified by PCR and restriction endonuclease 
(Figure 1B). The expression plasmid pET30-a was chosen 
because it provides the N-terminal 6伊His Tag and S. Tag 
sequence to the expressed proteins, which should facilitate 
protein purification by affinity purification methods. Tag-
encoded protein sequences can be removed from the 
resulting fusion proteins by cleavage with enterokinase. The 
sequencing results demonstrated that Rv3265c gene been 
cloned in this study was identical to the published sequence 
and there was no any change of base pair (GenBank 
Accession No.BX842582.1). 
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Figure 1. Amplification of Rv3265c gene and restriction endonuclease 
analysis of recombinant plasmid pET30-Rv3265c. 
(A) Rv3265c gene was amplified from Mycobacterium tuberculosis 
H37Rv genomic DNA by PCR. Lane M, DNA ladder; lane 1, PCR 
product. (B) Recombinant plasmid pET30-Rv3265c was identified 
by restriction endonuclease.  Lane M, DNA ladder; Lane 1, pET30-
Rv3265c was digested by BamHⅠand SacⅠ.
 
3.2. Expression and identification of L-rhamnosyltransferase 
protein
  L-rhamnosyltransferase was produced in E. coli BL21 
(DE3) cells carrying pET30-Rv3265c plasmid. Our attempts to 
induce the protein at a lower incubation temperature (30 曟), 
lower concentration of IPTG (0.1 mM) and short induction 
time (1h) in order to avoid inclusion bodies formation.
  L-rhamnosyltransferase fusing protein was observed on 
Coomassie blue R250 stained gel as expected 38 kDa band 
(Figure 2A). Analysis of the total and soluble fractions of 
the expressed L-rhamnosyltransferase fusing protein by 
SDS-PAGE demonstrated that the protein was localized 
premodinantly in the soluble fraction (Figure 2B). The 
L-rhamnosyltransferase was purified from the supernatant 
by passing through HIS-Select HF affinity gel. SDS-PAGE 
analysis of the purified sample showed single band slightly 
about 38 kDa (Figure 2C). Western blotting analysis of the 
same samples confirmed that the observed protein band 
reacted with the specific antibodies (Figure 2D).
M        1         2         3        4 M         1          2
94.0 kDa
66.2 kDa
45.0 kDa
35.0 kDa
26.0 kDa
20.0 kDa
M          1         2 1         2
94.0 kDa
66.2 kDa
45.0 kDa
35.0 kDa
26.0 kDa
20.0 kDa
A
B
C D
94.0 kDa
66.2 kDa
45.0 kDa
35.0 kDa
26.0 kDa
20.0 kDa
Figure 2. SDS-PAGE analysis and Western blotting identification 
of L-rhamnosyltransferase fusing protein expressed in E. coli BL21 
(DE3) cells.
 (A) SDS-PAGE analysis of total proteins expressed. Lane M, protein 
molecular mass standards; lane 1, cell lysate of bacteria transformed 
with pET30-Rv3265c without induction; lane 2, cell lysate of bacteria 
transformed with pET30-Rv3265c under 0.1 mM IPTG induction for 
1 h; lane 3, cell lysate of bacteria transformed with pET30-Rv3265c 
under 0.1 mM IPTG induction for 2 h; lane 4, cell lysate of bacteria 
transformed with pET30-Rv3265c under 0.1 mM IPTG induction for
3 h. (B) SDS-PAGE analysis of soluble and insoluble fractions 
proteins expressed. Lane M, protein molecular mass standards; lane 
1, induced pET30-Rv3265c in E. coli BL21 (DE3) by 0.1 mM IPTG 
for 1 h, supernatant; lane 2, induced pET30-Rv3265c in E. coli 
BL21 (DE3) by 0.1 mM IPTG for 1 h, pellet. (C) SDS-PAGE analysis 
of purified L-rhamnosyltransferase fusing protein expressed. Lane 
M, protein molecular mass standards; lane 1, negative control; lane 
2, the protein purified by affinity chromatography from supernatant 
induced pET30-Rv3265c in E. coli BL21 (DE3) by 0.1 mM IPTG for 
1 h. (D) Western blotting analysis of L-rhamnosyltransferase fusing 
protein. lane 1, negative control; lane 2, Western blotting analysis 
of L-rhamnosyltransferase fusing protein. The arrow indicates the 
location of the recombinant fusion protein.
3.3. Characteristics and structures of L-rhamnosyltransferase 
protein from bioinformatics analysis
  L-rhamnosyltransferase from Mycobacterium tuberculosi 
composes 301 amino acids with an estimated molecular 
mass of 33.3kDa and a pI value of 9.98. This protein has 
an N-terminal glycosyl transferase domain, no signal 
peptide and transmembrane helices, locates outside 
of membrane (Figure 3). The amino acids sequence of 
L-rhamnosyltransferase from Mycobacterium tuberculosis 
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Figure 5. Secondary structure prediction of L-rhamnosyltransferase. 
H: 毩-helix, E: extended strand, C: random coil.
 
Figure 6. The 3D structure of L-rhamnosyltransferase and the spacial 
localization of possible epitopes (white segments). 
H37Rv had the highest genetic relationship and showed 
100% homology with Mycobacterium tuberculosis H37Ra, 
Mycobacterium tuberculosis F11 and Mycobacterium 
tuberculosis CDC1551, but lower homology with other 
Mycobacterium (<80%) and lowest homology with other 
bacteria except Mycobacterium (<50%) (Figure 4). Secondary 
structure analysis revealed that the protein contained 毩
-helix (46.8%), extended strand (14.6%) and random coil 
(38.6%) (Figure 5). It possesses six potential antigenic 
epitopes, VTYSPGPHLERFLASLSLATERPVSVLLAD (4-33), 
PQAAVQRYPNVRLLPT (41-56), PVGWLSGSCLLVRR (173-186), 
GWLSVYVPSAEVLHHK (216-237), PASHLAAHHKSTYIFLAD (239-
256), LRGSLALRSHLMVRS (270-284), respectively(Figure 6). 
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Figure 3. Prediction of subcellular location and transmembrane 
helices of L-rhamnosyltransferase.
 
Aeromonas hydrophila 
Strepotococous pneumoniae
Salinibacter ruber DSM 13855
Saccharopolyspora erythraea NRRL 2338
Coryhebacterium giutamicum ATCC 13032
Leifsonia xyli subsp. xyli str. CTCB07
Themoplasma volcanium GSS1
Mycobacterium ayium 104
Mycobacterium marinum M
Mycobacterium tuberoulosis H37Rv
Mycobacterium leprae
Mycobacterium smegmatis
Halobacterium sp. NRC.1
Pytococcus abyssi GE5
Clostridium acetobutylicum ATCC 824
Peotobacterium atrosepticoum SCR11043
Fulyimarina pelagi HTCC2506
Escherichia coli
Vibrio vulnificous
Roseovarius sp. 217
Thetmotoga sp. RQ2
Thermus thermophilus HBB
Vibrio cholerae AM-19226
Shigella dysenteriae
Sphingomonas elodea
Vibrio parahaemolytious AQ3810
Thiobacillus denitrific ans ATCC 25259
Aotinobacillus pleuropneumoniae
Methanosarcina acetivorans C2A
Serratia matcescens
Flavobacterium psychrophilum JIP02/86
Klebsiella pneumoniae
Sammonella enterica
Figure 4. Evolution tree according to L-rhamnosyltransferase from other species.
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4. Discussion 
  Although tuberculosis remains a serious global public 
health threat due to the serious problem of drug resistance, 
particularly multi-drug resistant-tuberculosis, and 
tuberculosis associated with HIV infection, technologies for 
diagnosis, treatment, and prevention for tuberculosis are old 
and inadequate[8,9]. There is concurrent agreement that new 
anti-tuberculosis drugs are needed to shorten or simplify 
treatment. Despite ten compounds have being evaluated 
in clinical trials in the past decade, the global drugs 
pipeline for tuberculosis is still insufficient to address the 
unmet needs of treatment[10]. Mycobacterium bovis Bacillus 
Calmette-Guérin (BCG) vaccine is the only currently 
available licensed vaccine against tuberculosis now[11]. 
Although effective against development of tuberculosis 
in some countries, its effectiveness has been questioned 
in several studies, most notably in India, where very 
limited or no protection has been reported[12]. Therefore, 
the development of new therapeutic vaccine as well as 
new prophylactic vaccine against tuberculosis is urgently 
needed.
  Looking for novel candidates or targets is first step of 
development of drugs and vaccines against tuberculosis. 
Better understanding of Mycobacterium tuberculosis cell wall 
biosynthesis is required in order to elucidate the targets of 
existing drugs and vaccines to find new ones[13]. Essential 
genes of Mycobacterium tuberculosis growth in vitro and 
survival in vivo are main targets for anti-tuberculosis 
drugs development now[14]. The possibility of the protein 
encoded by Rv3265c gene of Mycobacterium tuberculosis is a 
putative rhamnosyltransferase which is needed for growth of 
mycobacteria[15-17]. 
  The completion of Mycobacterium tuberculosis genome 
sequences has greatly facilitated identification of a large 
numbers of targets and antigens with potential in anti-
tuberculosis drugs and vaccines[18,19]. Bioinformatics 
analysis is a powerful tool for protein identification, 
study of its localization, modification, function and 
possible interaction. Both sequences and structures of 
L-rhamnosyltransferase are conservative and especial. It 
located outside of membrane and posses potential antigenic 
epitopes. Accordingly, L-rhamnosyltransferase is a 
potential and suitable molecular target to develop new anti-
tuberculosis drugs and vaccines.
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